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BACKGROUND: Temozolomide shows activity against medulloblastoma, the most common malignant paediatric brain tumour.
Poly(ADP-ribose) polymerase (PARP) inhibitors enhance temozolomide activity in extracranial adult and paediatric human
malignancies.
METHODS: We assessed the effect of AG-014699, a clinically active PARP inhibitor, on temozolomide-induced growth inhibition in
human medulloblastoma models. Pharmacokinetic, pharmacodynamic and toxicity assays were performed in tumour-bearing mice.
RESULTS:Sensitivity to temozolomide in vitro was consistent with methylguanine methyltransferase (MGMT) and DNA mismatch repair
(MMR) status; MGMT
þ MMR
þ D384Med cells (temozolomide GI50¼220mM), representative of most primary medulloblastomas,
were sensitised fourfold by AG-014699; MGMT
  MMR
þ D425Med cells were hypersensitive (GI50¼9mM) and not sensitised by
AG-014699, whereas MGMT
þ MMR
  temozolomide-resistant D283Med cells (GI50¼807mM) were sensitised 20-fold. In xenograft
models, co-administration of AG-014699 produced an increase in temozolomide-induced tumour growth delay in D384Med
xenografts. Consistent with the in vitro data, temozolomide caused complete tumour regressions of D425Med xenografts, whereas
D283Med xenografts were relatively resistant. AG-014699 was not toxic, accumulated and reduced PARP activity X75% in
xenograft and brain tissues.
CONCLUSION: We show for the first time central nervous system penetration and inhibition of brain PARP activity by AG-014699.
Taken together with our in vitro chemosensitisation and toxicity data, these findings support further evaluation of the clinical potential
of AG-014699–temozolomide combinations in intra-cranial malignancies.
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Medulloblastoma is the most common malignant paediatric brain
tumour and accounts for almost 10% of all childhood cancer
deaths. The clinical outcome for patients with medulloblastoma is
variable and overall B40% of children with medulloblastoma will
die of their disease (Pizer and Clifford, 2008, 2009). Current
therapies for medulloblastoma comprise maximal surgical resec-
tion, craniospinal irradiation and chemotherapy. The use of these
combined modalities has led to long-term survival rates of B80%
in standard risk cases and B40–60% in high-risk cases (infants
o3 years or metastatic disease at presentation). However, the
development of relapsed, drug-resistant disease is common,
particularly in high-risk cases (B50%) and long-term side effects
associated with these therapies, including intellectual and neuro-
endocrine impairment associated with craniospinal irradiation
(reviewed in Pizer and Clifford, 2009). New therapeutic approaches,
particularly those that may result in improved therapeutic outcome
and reduced long-term sequelae, are clearly warranted.
Temozolomide shows significant single-agent activity in adult
oligodendrogliomas and high-grade astrocytomas and evidence of
activity in pre-clinical medulloblastoma models (Friedman et al,
1995; Middlemas et al, 2000; Macdonald, 2001; van den Brent et al,
2003). Recently, Phase I and II trials of temozolomide, using a
variety of schedules, have been undertaken in paediatric brain
tumour patients, including medulloblastoma (reviewed in Barone
et al, 2006). The maximum-tolerated dose and dose-limiting
toxicities in paediatric patients appear to be similar to those in
adults, and encouraging responses have been observed against
medulloblastoma (Baruchel et al, 2006; Nicholson et al, 2007;
Wang et al, 2009), supporting further investigation of temozolo-
mide in this disease.
DNA damage signalling and repair pathways are novel and
promising targets for improved cancer therapy, particularly with
regard to radio- and chemosensitisation. Genomic instability,
which often results from DNA damage signalling and repair
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sdefects, is a common characteristic of cancer. Such defects can
render the cancer cell more dependent on complementary
signalling and repair pathways, which are often upregulated.
These upregulated pathways can compromise the efficacy of DNA-
damaging anticancer agents and represent a novel therapeutic
target to specifically sensitise cancer cells (reviewed in Curtin,
2007). Resistance to temozolomide therapy has been associated
with high levels of methylguanine methyltransferase (MGMT) and
defects in mismatch repair (MMR) (Curtin et al, 2004). In adult
glioma patients, sensitivity to temozolomide is associated with
methylation of the MGMT promoter (Hegi et al, 2005). Attempts to
modulate temozolomide resistance through inhibition of MGMT
with co-administration of O
6-benzylguanine have not lived up to
their pre-clinical promise in adult brain tumour patients (reviewed
in Curtin, 2007). This approach has also been tested in the Phase I
setting in children, but the numbers are too small to determine if
success is likely to be greater (Broniscer et al, 2007). In the
pre-clinical setting, defects in DNA MMR are associated with
resistance to temozolomide, which is not overcome by MGMT
inhibition (Curtin et al, 2004; Cheng et al, 2005). In the Phase I
O
6-benzylguanine combination study, microsatellite instability, an
indication of defective MMR, was observed in four of the six
medulloblastoma patients. The MGMT status of primary medullo-
blastomas is controversial, with variable estimates in the literature,
although in general MGMT defects appear relatively uncommon
(reviewed in Lindsey et al, 2005). Similarly, in other studies,
MMR defects occur only in a small subset of medulloblastomas
(Viana-Pereira et al, 2009).
An alternative strategy to enhance temozolomide activity is
to inhibit poly(ADP-ribose) polymerase-1 and -2 (PARP-1 and
PARP-2). These enzymes are activated by DNA single- and double-
strand breaks and promote their repair through the relaxation of
chromatin and recruitment of other repair proteins. We have
previously shown that PARP inhibitors can restore temozolomide
sensitivity to MMR-defective cells (Curtin et al, 2004), and
sensitise tumour cells and xenografts, including models competent
for MMR and MGMT, to temozolomide (Calabrese et al, 2004). The
first PARP inhibitor to enter clinical trial for cancer therapy was
AG-014699, in combination with temozolomide (Plummer et al,
2008), which was selected on the basis of pre-clinical data in
models of adult human malignancies (Thomas et al, 2007).
AG-014699 has favourable pharmacokinetics and causes profound
and sustained inhibition of PARP activity in surrogate normal
tissues (peripheral blood lymphocytes) and tumours (Plummer
et al, 2008). In the Phase II setting, AG-014699 doubled the
reported response rate to temozolomide (Plummer et al, 2006). We
have recently been investigating the potential of AG-014699 in
models of paediatric malignancies and found that it increased the
efficacy of temozolomide and topotecan in neuroblastoma cells
and xenografts (Daniel et al, 2009).
We wished to investigate if AG-014699 could be beneficial for
the treatment of intra-cranial tumours, using medulloblastoma as a
model. Central nervous system (CNS) tumours can be more
difficult to treat because of the blood–brain barrier (BBB) that
limits drug uptake into CNS tissues. The BBB is a physical and
biochemical impediment to the transport of drugs into the CNS by
virtue of highly impenetrable vascular endothelial cells and an
abundance of drug efflux pumps (reviewed in Deeken and Loscher,
2007). In general, for good CNS penetration, drugs should have few
hydrogen bond donors and positive charges, lower polar surfaces,
reduced flexibility and be o400Da in size (Deeken and Loscher,
2007). AG-014699 is the phosphate salt of the active compound
AG-014447, which has a molecular weight of 323Da, pKa of 9.6 and
a clogD of 0.7 (Thomas et al, 2007). It is likely to exist as a
protonated amine at physiological pH and has some polar
functionalities that may not favour CNS penetration. The BBB
has been hypothesised to be less intact in primary and metastatic
brain tumours, at least in the case of large tumours, in which the
physiology of the endothelial cells is different from the rest of the
brain (reviewed in Daniel et al, 2009). However, a number of
other PARP inhibitors, including ones with similar structure to
AG-014447, have been shown to penetrate and have biological
activity in the brain in pre-clinical models of adult malignancies
(Tentori et al, 2003; Hattori et al, 2004; Donawho et al, 2007).
Recent clinical trials of the PARP inhibitor, olaparib, showed
evidence of regression in a brain metastasis in one patient (Fong
et al, 2009). Temozolomide shows good CNS penetration, and
uptake into human gliomas was higher than the surrounding
normal brain, owing to breakdown of the BBB and possibly
tumour-induced angiogenesis (Rosso et al, 2009). Furthermore,
radiotherapy can also disrupt the BBB (reviewed in Deeken and
Loscher, 2007). However, it may be hypothesised that, for smaller
tumours including the CNS metastatic deposits commonly
associated with medulloblastoma relapse, the BBB may still be
intact. It is therefore important to determine if AG-014699 can
penetrate CNS tissues.
We report here the pre-clinical assessment of AG-014699,
in vitro and in vivo in human medulloblastoma models. Our data
show the distribution of AG-014699 and inhibition of PARP in
CNS tissue for the first time and show the clear potential of PARP
inhibitors in combination with temozolomide for the improved
therapy of medulloblastoma.
MATERIALS AND METHODS
Materials
Temozolomide was a gift from Cancer Research UK (London, UK),
and AG-014699 (PO4 salt of AG-014447, now also called
PF-01367338) was a gift from Pfizer Oncology (La Jolla, CA,
USA). Temozolomide was dissolved in dimethyl sulphoxide
(DMSO) before addition to cell cultures at a final concentration
of 0.5% (vv
 1) DMSO. For in vivo evaluation, temozolomide was
dissolved in saline immediately before administration. 10H mouse
monoclonal antibody to ADP-ribose polymers was a kind gift from
Dr Alexander Burkle (University of Konstanz, Konstanz,
Germany). Other chemicals and reagents were obtained from
Sigma (Poole, UK), unless otherwise stated.
Cell lines and culture
Three medulloblastoma cell lines were selected for study. D384Med
and D425Med were kind gifts from Dr D Bigner (Duke University,
Durham, NC, USA). D283Med was obtained from the American
Type Culture Collection (Manassas, VA, USA). Published cell line
karyotypes and genetic features were confirmed in each cell line
before use; all three lines harboured genetic lesions consistent with
primary medulloblastomas (Langdon et al, 2006). All three
medulloblastoma cell lines were maintained using standard
methods, in Dulbecco’s modified Eagle’s medium containing
20% fetal calf serum (Life Technologies, Paisley, UK), and were
confirmed to be mycoplasma free.
Cell line protein expression
Protein lysates were prepared from each cell line using standard
methods and examined for the presence of the PARP-1
protein (H-250 anti-PARP-1 antibody; Santa Cruz Biotechnology,
Heidelberg, Germany) and a-tubulin control using western blot
analysis (50mg protein loaded per well). Lysates were also blotted
for cell line expression of MGMT and the MMR proteins MLH1,
MSH2, MSH3, MSH6 and PMS2 (all mouse monoclonal antibodies;
BD Biosciences Pharmingen, Oxford, UK).
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Inhibition of PARP activity in 5000 exponentially growing
D283Med cells was measured following treatment with a range of
AG-014699 concentrations (0–1mM), in comparison with DMSO-
only controls. Maximally stimulated PARP activity was measured
in replicate samples (nX3) of permeabilised cells by immuno-
logical detection of the amount of poly(ADP-ribose) (PAR)
formed, using 10H anti-PAR antibody, during a 6-min incubation
with NAD
þ and oligonucleotide (substrate and activator) by
reference to a PAR (Biomol Research Labs, Plymouth, PA, USA)
standard curve using a GCLP-validated assay described previously
(Plummer et al, 2005).
In vitro growth inhibition and cytotoxicity assays
Cell growth inhibition was estimated in exponentially growing
D425Med, D283Med and D384Med cells in 96-well plates. Seeding
densities of 1 10
3,3 10
3 and 3 10
3 cells, respectively, ensured
exponential growth for the duration of the experiment. At 24h
(D384Med) or 48h (D283Med and D425Med) after seeding, cells
were exposed to varying concentrations of temozolomide, as
described in the Results, in the presence or absence of 0.4mM
AG-014699, a concentration previously shown to enhance
temozolomide cytotoxicity in adult tumour cell lines (Thomas et al,
2007). After 3 days (D425Med and D384Med) or 5 days (D283Med)
of culture (equivalent to approximately three cell divisions), the
cell viability was quantified using an XTT cell proliferation kit
assay (Roche, Mannheim, Germany), according to the manufac-
turer’s instructions. Cell growth was expressed as a percentage in
relation to DMSO or 0.4mM AG-014699-alone controls. The
concentration of temozolomide, alone or in combination with
AG-014699, that inhibited growth by 50% (GI50) was calculated
from computer-generated curves (GraphPad Software, San Diego,
CA, USA). The potentiation factor50 (PF50) is defined as the ratio of
the GI50 of temozolomide in the presence of AG-014699 to the GI50
of temozolomide alone. All data were from at least three
independent experiments.
Establishment of D425Med, D283Med and D384Med
tumour xenografts
All of the in vivo experiments were reviewed and approved by the
relevant institutional animal welfare committees, and performed
according to national law. Female athymic nude mice (CD1 nu/nu;
Charles River, Margate, UK) used for anti-tumour studies were
maintained and handled in isolators under specific pathogen-free
conditions. D425Med, D283Med and D384Med (1 10
7 exponen-
tially growing cells per mouse, harvested and implanted in growth
media) xenografts were established by sub-cutaneous implantation
into CD-1 nude mice. Before use in experiments, xenograft
establishment was defined as when two-dimensional calliper
measurements of tumours reached approximately 5 5mm
2.
Treatment was initiated when sufficient number of mice had
established tumours to allow randomisation into treatment groups:
day 17 for D425Med, day 26 for D384Med and day 32 for
D283Med. Tumour-bearing mice were killed 100 days after the
start of treatment or when two dimensions of a tumour xenograft
reached 10mm or one dimension reached 15mm, whichever was
the earliest.
AG-014699 pharmacokinetics and pharmacodynamics in
mouse plasma, brain and D283Med tumour xenografts
One or four daily doses of PARP inhibitor AG-014699 (1mgkg
 1
intraperitoneally (i.p.)) were given to CD-1 nude mice bearing
established D283Med xenografts. At 0.5, 2, 6 and 24h after the
initial or fourth daily dose of AG-014699, three animals per time
point were bled by cardiac puncture under general anaesthesia,
and then killed. Plasma was separated from the blood samples
using standard methods and stored at  801C. The brains and
tumours were removed, snap frozen in liquid nitrogen and stored
at  801C before analysis. Blood, tumour and brain tissue were
removed from three untreated control animals and processed in
the same way.
AG-014699 distribution in plasma, brain and tumour
xenograft samples
AG-014699 is the phosphate salt of AG-014447 and rapidly
liberates the parent drug following injection. The concentration
of AG-014447 was determined in plasma and tissue homogenates
(1:4 (wv
 1) in PBS) of brain and tumour after protein
precipitation with acetonitrile by liquid chromatography/mass
spectrometry/mass spectrometry using a turbo ion spray interface
and multiple reaction monitoring in the positive ion mode (API
4000; Applied Biosystems, Warrington, Cheshire, UK) and a
deuterated internal standard as described previously (Plummer
et al, 2008). The lower limit of quantitation was 1ngml
 1. Plasma
pharmacokinetics of AG-014447 were analysed using a non-
compartmental approach in WinNonlin version 5.2.
Pharmacodynamics in brain and tumour tissue: PARP-1
activity assays
PARP activity was determined in homogenates of subcutaneous
D283Med xenografts and brain tissue (see above). Maximally
stimulated PARP activity was measured in replicate samples
(nX3) of a 1:1000 dilution of the homogenate as described
for permeabilised D283Med cells (see above). Data were calculated
as pmol PAR per mg protein by reference to the PAR standard
curve and protein content of the sample and expressed as a
percentage of the corresponding tissue from the saline-treated
control animals. The mean PARP activity in xenograft and
brain samples taken at each time point was expressed as a
percentage of the mean PARP activity of control xenografts from
untreated mice (n¼3).
Tumour growth inhibition in vivo
CD-1 nude mice bearing palpable, established subcutaneous
D425Med, D283Med and D384Med xenografts were treated with
normal saline (control animals), temozolomide (68mgkg
 1 per os
(p.o.)) or AG-014699 (1mgkg
 1 i.p.) alone or in combination,
daily for 5 days (five mice per group). For drug combinations,
AG-014699 was administered immediately after administering
temozolomide. Tumour volumes, determined from two-
dimensional calliper measurements and the equation a
2 b/2
(where a is the length and b is the width of the tumour), were
monitored for the experimental period (up to 100 days), and are
presented for each group of mice as median relative tumour
volume (RTV) values. Relative tumour volume 1 is the tumour
volume on the initial day of treatment (day 0), and RTV4 is the
tumour volume four times that on the initial day of treatment.
Tumour growth delay (TGD) is defined as the time to RTV4 in
drug-treated mice compared with the time to RTV4 in control
(vehicle alone) mice. Median tumour volume is shown, rather than
the mean, as this is generally accepted as the most statistically
reliable representation of the average growth rate of tumours
in a small group of mice, if a normal distribution of tumour
volumes cannot be assumed. Tumour growth delay was calculated
as: median time to RTV4 in treated group median time to
RTV4 in control group. Percentage enhancement was calculated as
100 (TGD TMZþAG-014699/TGD TMZ alone) 100 (Calabrese
et al, 2004).
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AG-014699 and PARP-1 inhibition in permeabilised
medulloblastoma cells
AG-014699 is a potent inhibitor of purified full-length human
PARP-1 (Thomas et al, 2007). We assayed PARP-1 activity in
permeabilised D283Med cells after AG-014699 treatment.
AG-014699, at concentrations of 0.1, 0.4 and 1mM, inhibited
PARP-1 activity by 81.1, 96.8 and 97.1%, respectively. All previous
cellular chemosensitisation studies with this class of PARP
inhibitor, including AG-014699 have used a concentration of
0.4mM (Calabrese et al, 2004; Thomas et al, 2007). As this
concentration also caused almost total inhibition of the PARP
activity in medulloblastoma cells, we used a concentration of
0.4mM AG-014699 to study the chemosensitisation of temozolo-
mide, enabling comparison with previous data.
Cell line expression of inhibition target and DNA repair
pathway proteins
All three cell lines selected for study expressed PARP-1 by western
blotting (Figure 1). D384Med also clearly expressed MGMT and the
MMR proteins MLH1, MSH2, MSH3, MSH6 and PMS2, indicating
competence in these pathways implicated in temozolomide
sensitivity. However, two of the cell lines were found to be
compromised in the expression of some of these proteins.
D425Med lacked MGMT and D283Med was deficient in MLH1
and had barely detectable PMS2, indicating MMR dysfunction.
Potentiation of temozolomide induced growth inhibition
by AG-014699
We measured the growth of cells exposed to increasing
concentrations of temozolomide alone or in combination with
0.4mM AG-014699 continuously, over a period of three cell
doublings. Representative growth inhibition curves of D425Med
(Figure 2A), D283Med (Figure 2B) and D384Med (Figure 2C) are
shown. Pooled GI50 data for temozolomide with and without
AG-014699 from at least three independent experiments for each of
the three cell lines are shown in Table 1. AG-014699 alone was not
growth inhibitory at the concentration used (0.4mM) (data not
shown). Temozolomide alone caused a concentration-dependent
inhibition of growth in all three cell lines. Cell lines exhibited
variable levels of sensitivity to temozolomide alone. The MGMT-
deficient D425Med cells were hypersensitive to temozolomide, and
the MMR-defective D283Med cells were nearly 100 times less
sensitive, as expected. The D384Med cells, which were proficient
in both pathways, displayed intermediate sensitivity. There was
also considerable variation in the degree of chemosensitisation
by AG-014699 between the cells, with almost 20-fold sensitisation
of the MMR-defective, D283Med, cells compared with 43-fold
sensitisation in the MMR- and MGMT-competent D384Med cells,
but no sensitisation of the MGMT-deficient, D425Med, cells.
AG-014699 levels in plasma, brain tissue and D283Med
tumour xenografts
A dose of 1mgkg
 1 AG-014699 daily five times has previously
been shown to be non-toxic and sufficient for profound
chemosensitisation of human colon and neuroblastoma cancer
xenografts to temozolomide (Thomas et al, 2007; Daniel et al,
2009). Therefore, we selected this dose to investigate chemo-
sensitisation of medulloblastoma xenografts. Before undertaking
these studies, we determined the distribution of the PARP
inhibitor in the plasma, and to brain and tumour tissue, following
a single dose and four daily doses of 1mg AG-014699 per kg i.p. in
mice bearing D283Med sub-cutaneous xenografts. We measured
concentrations of AG-014447 at either 0.5, 2, 6 or 24h after dosing
(three mice per time point).
After the first dose of AG-014699 (Figure 3Ai), a peak plasma
concentration of 56±13ngml
 1 (172±39mM) AG-014447 was
detected at the earliest time point after injection. Thereafter, the
levels decreased rapidly, such that at 24h they were below the level
of quantitation.
Levels in the tumour were higher than that in the plasma at all
time points (Figure 3A), for example, 230–1510nM in the tumour
compared with 131–209nM in plasma at 30min. There was also
significant and prolonged retention within the tumour, such that at
24h after injection, levels of between 74 and 196nM were still
detectable. Surprisingly, given its physical and chemical proper-
ties, significant levels of AG-014447 were also detected in the brain
tissue. Although these were initially lower than those in the plasma
(20–40nM at 30min), there was some degree of retention such that
at 24h the levels were up to 10-fold higher than that in the plasma
(1–30nM in brain compared with 1.9–2.4nM in plasma). After the
fourth daily dose of AG-014699 (Figure 3Aii), peak plasma
AG-014447 concentrations were similar to those following a single
dose. Levels in the brain were only marginally greater than plasma
levels at 6h. However, high concentrations (639–932nM) were
retained in the tumour for the entire period. In the plasma, AUCs
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Figure 1 Protein expression levels of PARP-1 and proteins related to
temozolomide sensitivity/resistance in medulloblastoma cell lines. Expres-
sion levels of a-tubulin (control) are also shown. Protein expression was
determined for 50mg of whole-cell lysate by western blot analysis and
visualised by chemoluminescence. D425 cells have no detectable MGMT
and D283 cells have no detectable MLH-1 and minimal PMS2 consistent
with MGMT and mismatch repair deficiency, respectively, whereas D384
cells are proficient for both.
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s(26.4 and 21.9mmoll
 1min on days 1 and 4) and half-life
(299 and 254min) were similar to those reported previously
(Thomas et al, 2007). The AUCs in the brain (37.0 and
14.7mmoll
 1min on days 1 and 4) were comparable to those in
the plasma, whereas AUCs in tumour were substantially higher
(582.0 and 509.6mmoll
 1min).
Consistent with the AG-014447 distribution data, PARP activity
was suppressed in both brain and tumour tissue following
administration of AG-014699. In the brain, PARP activity was
reduced by around 75% for the first 2h, recovering gradually
thereafter, such that it was approximately 40% reduced at 24h
(Figure 3Bi). After the fourth daily dose, however, there was less
suppression and more rapid recovery such that near-normal
activity was detected at 24h (Figure 3Bii). This presumably reflects
the lower AUC of the drug in this tissue after the fourth dose.
In contrast, in the tumour, inhibition of PARP activity was
slightly delayed, reaching a nadir of around 75% reduction at 6h
post-injection, which was similar (barring obvious outlier data)
after the first and fourth dose (Figure 3Ci and ii). The modest
recovery at 24h did appear greater after the fourth dose than the
first, however.
Efficacy of temozolomide with AG-014699 in human
tumour xenografts
We examined the effect of AG-014699 on the anti-tumour activity
of temozolomide in mice bearing established subcutaneous
D425Med, D283Med or D384Med xenografts. Mice were treated
daily for 5 days with either vehicle control alone, AG-014699 alone
(1mgkg
 1 i.p.), TMZ alone (68mgkg
 1 p.o.) or the combination
of TMZ (68mgkg
 1 p.o.)þAG-014699 (1mgkg
 1 i.p.) data are
summarised in Table 2.
At 1mgkg
 1 daily five times, AG-014699 alone did not cause
any marked toxicity or affect tumour growth compared with
vehicle-only controls. The D425Med cells grew relatively slowly
(median time to RTV4¼19 days) and, as expected from the
in vitro data, were very responsive to temozolomide alone with
complete tumour regressions seen in all mice (Figure 4A). These
regressions were sustained for the designated experimental
period (100 days) in two out of five mice. Co-administration
of AG-014699 with temozolomide also resulted in complete tumour
regressions in all mice, of which three out of five were
sustained throughout the experiment. The MMR-defective D283Med
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Figure 2 Chemosensitisation to TMZ by AG-014699 in vitro in medulloblastoma cell lines. (A–C) Growth inhibition of D425Med, D283Med and
D384Med cells, determined by XTT assay following a 6-day exposure to TMZ either alone (solid triangles) or with 0.4mM AG-014699 (open triangles). Data
are shown normalised to 0.5% DMSO or 0.4mM AG-014699 controls, respectively. A single representative replicate for TMZ±0.4mM AG-014699 in
D425Med (A), D283Med (B) and D384Med (C) cells (±95% confidence intervals (CI)) is shown.
Table 1 Growth inhibition by temozolomide and sensitisation by AG-014699
Cell line GI50 temozolomide (lM)G I 50 temozolomideþAG-014699 (lM)P F 50
D425Med 9.3±7.5
a 13.3±3.2 0.7±0.4
D283Med 807±239 42±15* 19±4.7
D384Med 220±42 60±13** 3.8±1
Abbreviations: GI50¼inhibition of growth by 50%; PI50¼potentiation factor50.
aData are means and standard deviation of three independent experiments of the type shown in
Figure 2. *Significantly different from temozolomide alone (P¼0.005, Student’s two-tailed t-test). **Significantly different from temozolomide alone (P¼0.003, Student’s
two-tailed t-test).
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sxenografts grew very rapidly (median time to RTV4¼7 days)
and showed very little response to temozolomide alone (TGD
of only 2 days) with no regressions observed in any mice
(Figure 4B). In contrast to the pronounced in vitro sensitisation,
co-administration of AG-014699 only increased this TGD to
2.5 days. The D384Med xenografts, proficient in both MGMT
and MMR pathways of DNA repair, grew at an intermediate
rate (median time to RTV4¼16 days). Temozolomide alone
caused a significant TGD (P¼0.016), extending the time to
RTV4 to 44.5 days (Figure 4C), and the combination with
AG-014699 the time to RTV4 was 62 days. Thus, the temozolomide-
induced TGD of 28.5 days was extended to 46 days by
co-administration of AG-014699, equivalent to a 61% increase
in efficacy; however, this was not quite significant (P¼0.11
Mann–Whitney test). There was one transient complete response
seen in both the temozolomide alone and the temozolomideþ
AG-014699 groups. Temozolomide alone caused a modest (5±4%),
but statistically significant, weight loss relative to control
(P¼0.0006, unpaired t-test). AG-014699 was not toxic per se
(1±1% body weight loss), but caused a modest, but significant,
enhancement of temozolomide-induced body weight loss (10±6%
weight loss: P¼0.013, unpaired t-test).
DISCUSSION
In the work described here, we sought to address the need for
new therapeutic approaches to improve outcome in medullo-
blastoma. Temozolomide shows good activity in adult glio-
blastomas (Mrugala and Chamberlain, 2008) and encouraging
data are emerging from Phase I and II studies in paediatric intra-
cranial malignancies, including medulloblastoma (Barone et al,
2006; Baruchel et al, 2006; Nicholson et al, 2007; Wang et al, 2009).
We assessed the efficacy of temozolomide alone, and in combina-
tion with the PARP inhibitor AG-014699 in medulloblastoma,
using three models (D384Med, D425Med and D283Med), which are
genetically representative of the primary disease (Langdon et al,
2006). We also investigated pharmacokinetics, pharmacodynamics
and toxicity of AG-014699, and show for the first time uptake into
CNS and significant and sustained PARP inhibition in brain tissue.
We initially investigated in our models the status of mole-
cular pathways implicated in the modulation of temozolomide
sensitivity (i.e. DNA MMR and MGMT; Middlemas et al, 2000).
Our cell lines modelled closely the diversity observed in primary
medulloblastomas; D384Med cells were proficient for all proteins
tested, indicating they reflect the vast majority of primary
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Figure 3 AG-014699 pharmacokinetics and PARP-1 inhibition in mouse brain and medulloblastoma xenograft. Following a single (i) or the last of
four daily doses (ii) of AG-014699 (1mgkg
 1, i.p.), samples were taken and tissues harvested at the indicated times post-administration: (A) concentration
of AG-014447 in plasma (solid triangle), brain (open circle) and D283Med xenograft homogenates (solid circle) from tumour-bearing mice. Corresponding
PARP-1 activity in D283Med xenograft homogenates (B) and the brain (C) is shown. Concentrations of AG-014447 are given as the mean (±95% CI)
from three tumour-bearing mice per time point; PARP activity measurements are given as individual values with the horizontal lines indicating the
mean value.
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smedulloblastomas, in which MMR deficits (observed in B10% of
cases; Viana-Pereira et al, 2009) and MGMT hypermethylation
(B25% of cases; Lindsey et al, 2005) are relatively uncommon.
Data for our other cell lines were consistent with their relevance as
models of primary cases associated with MMR (D283Med) and
MGMT (D425Med) deficiency. In subsequent efficacy testing, the
MGMT-deficient D425Med cells were very sensitive to temozolo-
mide both in cell cultures and as xenografts, being nearly 25 times
more sensitive than the MGMT-proficient D384Med cells in
culture, and showing complete tumour regressions in response
to temozolomide alone in in vivo experiments. The sensitivity of
D425Med to temozolomide alone may limit the usefulness of this
cell line in assessing sensitisation by inhibition of PARP.
Previous studies in paediatric xenografts have also concluded
that MGMT status is the major determinant of sensitivity to
temozolomide, but that MMR defects also confer resistance
(Middlemas et al, 2000). This was clearly illustrated in our panel
by MMR-defective D283Med cells, which were nearly four times
less sensitive to temozolomide than D384Med cells and xeno-
grafts derived from these cells showed barely any response to
temozolomide therapy. In cell culture experiments, AG-014699, at
a concentration that inhibited PARP by 495%, did not enhance
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Figure 4 Enhancement of TMZ efficacy by AG-014699 in in vivo models of medulloblastoma. Growth of D425Med (A), D283Med (B) or D384Med
(C) tumour xenografts over a 100-day period, following daily treatment for 5 days with vehicle control alone (solid circles), AG-014699 alone (1mgkg
 1,
open circles), TMZ alone (68mgkg
 1, solid triangles) or TMZ (68mgkg
 1)þAG-014699 (1mgkg
 1) (open triangles). Dashed horizontal line corresponds
to RTV4. Data are median of five mice per group until first humane killing owing to tumour burden.
Table 2 Toxicity and efficacy of TMZ and AG-014699 in medulloblastoma xenografts
Xenograft Treatment
Median nadir body
weight (% starting weight)
Median time
to RTV4 (days)
Tumour growth
delay (days) (% enhancement)
Complete
regressions
D425Med Control 98 19 0/5
AG-014699 98 15.5 0/5
TMZ 96 4100 481 2/5
Combination 95 4100 481 (N/A) 3/5
D283Med Control 98 7 0/5
AG-014699 100 8 1 0/5
TMZ 94 9 2 0/5
Combination 91 9.5 2.5 (25%) 0/5
D384Med Control 100 16 0/5
AG-014699 96 20 4 0/5
TMZ 97 44.5 28.5 1/5
Combination 90 62 46 (61%) 1/5
Abbreviations: N/A¼not applicable; RTV¼relative tumour volume; TMZ¼temozolomide; PI50¼potentiation factor50.
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stemozolomide sensitivity in the MGMT-defective cells, but caused
a striking 20-fold enhancement in the MMR-defective D283Med
cells. These observations are in line with our previous observations
in adult human cancer cell lines (Calabrese et al, 2004; Curtin et al,
2004; Thomas et al, 2007). These data reflect the molecular
pathology of the cells and hence the relative contribution that
O
6-methylguanine and N
7-methylguanine and N
3-methyladenine
(that are repaired by PARP-dependent processes) make to the
overall cytotoxicity of temozolomide in the individual cell lines.
In the in vivo chemosensitisation studies, co-administration of
AG-014699 caused an approximately 60% increase in temozolo-
mide-induced TGD in the DNA repair protein-competent
D384Med xenografts but, owing to the small sample number, the
effect was not significant (P¼0.11). In comparison, the D425Med
tumours grew relatively slowly and responded well to temozolo-
mide alone, with all mice showing complete tumour regressions,
two of which were sustained until the termination of the
experiment at 100 days. Xenografts from MGMT-deficient SW620
cells show similar sensitivity to temozolomide alone, but are
sensitised further by AG14361 and AG-014699 (Calabrese et al,
2004; Thomas et al, 2007), most probably because of the
vasoactivity of these PARP inhibitors (Ali et al, 2009). We had
therefore expected to see potentiation of temozolomide anti-
tumour activity in D425Med tumours by AG-014699. The number
of complete regressions persisting to the end of the experiment was
three out of five in the temozolomideþAG-014699 group,
compared with two out of five in the temozolomide alone. On
the basis of the small sample size, this cannot be considered
significant, but is nevertheless encouraging. The lack of sensitisa-
tion by AG-014699 of the anti-tumour effect of temozolomide in
MMR-defective D283Med xenografts was surprising, given the
degree of potentiation seen in vitro. The lack of effect of
AG-014699 in the D283Med xenografts was not due to PK/PD
limitations, as accumulation of AG-0144447 and substantial PARP
inhibition was shown in the tumours. MMR defects are observed in
only a minority of medulloblastomas and the lack of synergy in
this model does not undermine the rationale for combining PARP
inhibitors with temozolomide. Thus, in summary, we propose that
the D384Med model most faithfully reflects the clinical situation in
the majority of medulloblastoma cases. The indication of
chemosensitisation observed in this model is therefore encoura-
ging and warrants further investigation in a wider panel of
MMR- and MGMT-competent medulloblastoma models.
We have not previously determined the CNS penetration of
AG-014447, the free drug of which AG-014699 is the phosphate
salt, nor its inhibition of PARP activity in the brain. We saw
clear evidence of AG-014447 penetration into brain tissue, and
accompanying evidence of PARP inhibition, in mice with an intact
BBB. PARP activity in the brain was higher than expected for
a non-dividing tissue, with the activity being in the range
88–106pmol PAR per mg protein per min. Although significantly
lower than that detected in the associated tumour xenografts
(1402–3236pmol PAR per mg protein per min), it was comparable
with the activity detected in normal mouse liver and kidney
(98–106pmol PAR per mg protein per min in the livers,
69–76pmol PAR per mg protein per min in the kidneys,
unpublished observations). Although concentrations of
AG-014447 achieved in the brain (20–60nM) were lower than
were used for in vitro chemosensitisation, the inhibition of PARP
activity over the 24-h period was 50–80%. This level of inhibition
is in general agreement with the 80% inhibition of activity
seen in permeabilised cells exposed to 100nM AG-014699, and is
sufficient to cause in vivo chemosensitisation in models of both
adult and paediatric malignancies (Calabrese et al, 2004; Daniel
et al, 2009). Importantly, the peak plasma level in mice treated with
AG-014699 at 1mgkg
 1 was 42–68ngml
 1, which is approxi-
mately 1/10th the concentration in patients treated with the
recommended Phase II dose of 12mgm
 2 (473–675ngml
 1).
Therefore, higher drug levels and greater PARP inhibition should
be achievable in the brains of patients treated with a safe dose
of AG-014699. The observed accumulation of AG-014447 in
xenografted medulloblastomas, which is consistent with our data
for other tumour types coupled with a potentially compromised
blood–brain tumour barrier suggests that drug accumulation in
the tumours may be even higher. Further investigations
in orthotopic or spontaneous transgenic models of medulloblas-
toma could provide useful insights in this regard, although the
limitations of these models as representative of primary tumours
and an intact BBB must also be taken into account.
Several PARP inhibitors have been shown to penetrate CNS
tissue and to have a pharmacological effect, either in terms of an
enhancement of the anti-tumour activity of temozolomide against
intra-cranial tumours or reduction in focal ischaemia in a stroke
model (Tentori et al, 2003; Hattori et al, 2004; Cheng et al, 2005;
Donawho et al, 2007). Indeed, one of the indications of PARP
inhibitors is in the reduction of brain tissue damage following
stroke (Jagtap and Szabo, 2005). However, to the best of our
knowledge, this is the first time that inhibition of PARP activity in
the brains of mice treated with a PARP inhibitor has been shown.
In summary, the data we present here shows encouraging
enhancement of temozolomide activity in pre-clinical cell line
models of medulloblastoma, representative of the spectrum of
sensitivity to single-agent temozolomide. Furthermore, following a
non-toxic dose of AG-014699, good CNS penetration and
correspondingly substantial inhibition of PARP activity in nervous
tissue was observed in association with AG-014699 plasma levels
1/10th of those detected in patients treated with the recommended
Phase II dose, and without significant toxicity. Further vali-
dation of these observations in a wider range of cell lines and
in orthotopic models are required before a clinical evaluation of
AG-014699 in combination with temozolomide for intra-cranial
malignancies would be indicated.
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